Table 1.

Allogenic stem cell transplantation for CLL and Richter syndrome.

Study group	Diagnosis	N.	OS	PFS	NRM
Kim et al. (56)	CLL	108	87% (3 years)	68% (3 years)	7% (3 years)
Roeker et al. (57)	CLL	65	81% (2 years)	63% (2 years)	13% (2 years)
Lahoud et al. (58)	CLL	35	66% (2 years)	46% (2 years)	26% (2 years)
Cwynarski et al. (59)	RS	25	36% (3 years)	27% (3 years)	26% (3 years)
Kim et al. (60)	RS	28	53% (4 years)	39% (4 years)	29% (4 years)
Lahoud et al. (58)	RS	23	74% (2 years)	65% (2 years)	13% (2 years)
Herrera et al. (61)	RS	118	52% (3 years)	43% (3 years)	27% (3 years)
Kharfan-Dabaja et al. (62)	RS	19	50% (4 years)	50% (4 years)	40% (4 years)

CLL, chronic lymphocytic leukemia; NRM, non-relapse mortality; OS, overall survival; PFS, progression-free survival; RS, Richter syndrome.